RxSight, Inc. (NASDAQ:RXST – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last […]